Jacob M. Rowe

27.0k total citations · 5 hit papers
317 papers, 12.9k citations indexed

About

Jacob M. Rowe is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Jacob M. Rowe has authored 317 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 238 papers in Hematology, 138 papers in Public Health, Environmental and Occupational Health and 69 papers in Genetics. Recurrent topics in Jacob M. Rowe's work include Acute Myeloid Leukemia Research (159 papers), Acute Lymphoblastic Leukemia research (134 papers) and Chronic Myeloid Leukemia Treatments (80 papers). Jacob M. Rowe is often cited by papers focused on Acute Myeloid Leukemia Research (159 papers), Acute Lymphoblastic Leukemia research (134 papers) and Chronic Myeloid Leukemia Treatments (80 papers). Jacob M. Rowe collaborates with scholars based in Israel, United States and United Kingdom. Jacob M. Rowe's co-authors include Martin S. Tallman, Elisabeth Paietta, Hillard M. Lazarus, Mark R. Litzow, Selina M. Luger, Anthony H. Goldstone, Adele K. Fielding, D. Gary Gilliland, Georgina Buck and Peter H. Wiernik and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jacob M. Rowe

310 papers receiving 12.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anthracycline Dose Intensification in Acute Myeloid Leukemia

2009 639 citations Hugo F. Fernández, Zhuoxin Sun et al. profile →
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2006 591 citations Adele K. Fielding, Susan Richards et al. Blood profile →
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

2007 537 citations Anthony H. Goldstone, Susan Richards et al. Blood profile →
Drug therapy for acute myeloid leukemia

2005 512 citations Martin S. Tallman, Jacob M. Rowe et al. Blood profile →
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

2006 502 citations Georgina Buck, Adele K. Fielding et al. Blood profile →

Peers

Countries citing papers authored by Jacob M. Rowe

Since Specialization

Citations

This map shows the geographic impact of Jacob M. Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob M. Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob M. Rowe more than expected).

Fields of papers citing papers by Jacob M. Rowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob M. Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob M. Rowe. The network helps show where Jacob M. Rowe may publish in the future.

Co-authorship network of co-authors of Jacob M. Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob M. Rowe. A scholar is included among the top collaborators of Jacob M. Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob M. Rowe. Jacob M. Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study 2023 ·Bone Marrow Transplantation ·Joseph P. McGuirk, Leland Metheny, Luis Piñeiro, Mark R. Litzow, Scott D. Rowley, Batia Avni, Roni Tamari, Hillard M. Lazarus, Jacob M. Rowe, (unknown), (unknown), (unknown), Tsila Zuckerman	2
2	Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia 2021 ·British Journal of Haematology ·Peter H. Wiernik, Zhuoxin Sun, Larry D. Cripe, Jacob M. Rowe, Hugo F. Fernández, Selina M. Luger, Hillard M. Lazarus, Elisabeth Paietta, Martin S. Tallman, Mark R. Litzow	6
3	Perspectives on current survival and new developments in AML 2021 ·Best Practice & Research Clinical Haematology ·Jacob M. Rowe	18
4	Venetoclax is safe and efficacious in relapsed/refractory AML 2020 ·Leukemia & lymphoma ·Chezi Ganzel, Ron Ram, Alexander Gural, Ofir Wolach, (unknown), Vladimir Vainstein, Boaz Nachmias, Arie Apel, Maya Koren‐Michowitz, Oren Pasvolsky, Ronit Yerushalmi, Ivetta Danylesko, Yosef Cohen, (unknown), (unknown), Miri Zektser, (unknown), Jacob M. Rowe, Yishai Ofran	30
5	Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation 2019 ·Leukemia & lymphoma ·Ofrat Beyar‐Katz, Noa Lavi, (unknown), Israel Henig, (unknown), (unknown), Riva Fineman, Yishai Ofran, (unknown), Dvora Sahar, (unknown), Jacob M. Rowe, Tsila Zuckerman	10
6	BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study 2019 ·Blood Advances ·Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren‐Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, (unknown), Sigal Tavor, (unknown), Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, (unknown), Jacob M. Rowe	10
7	The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults 2017 ·Bone Marrow Transplantation ·Mark R. Litzow, Adele K. Fielding, Selina M. Luger, Elisabeth Paietta, Yishai Ofran, Jacob M. Rowe, Anthony H. Goldstone, Martin S. Tallman, H M Lazarus	13
8	The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma 2013 ·Clinical Cancer Research ·Amnon Peled, Michal Abraham, Irit Avivi, Jacob M. Rowe, Katia Beider, Hanna Wald, (unknown), (unknown), (unknown), (unknown), (unknown), Eithan Galun, (unknown), Orly Eizenberg, Izhar Hardan, Avichai Shimoni, Arnon Nagler	70
9	Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia 2012 ·Molecular Cancer Therapeutics ·Jeremy B. Samon, Mireia Castillo-Martín, Michael Hadler, (unknown), Elisabeth Paietta, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, John Jakubczak, Sophia Randolph, Carlos Cordon‐Cardo, Adolfo A. Ferrando	86
10	Pharmacokinetic and Pharmacogenetic Analysis of Oral Busulfan in Stem Cell Transplantation: Prediction of Poor Drug Metabolism to Prevent Drug Toxicity 2012 ·Current Drug Safety ·Norberto Krivoy, Tsila Zuckerman, (unknown), (unknown), Jacob M. Rowe, Edna Efrati	15
11	Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 2010 ·Blood ·Larry D. Cripe, Hajime Uno, Elisabeth Paietta, Mark R. Litzow, Rhett P. Ketterling, John M. Bennett, Jacob M. Rowe, Hillard M. Lazarus, Selina M. Luger, Martin S. Tallman	182
12	A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma 2010 ·Haematologica ·Eldad J. Dann, Rachel Bar‐Shalom, Ada Tamir, Ron Epelbaum, Irit Avivi, Menachem Ben‐Shachar, Diana Gaitini, Jacob M. Rowe	20
13	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) breakdown → 2007 ·Blood ·Anthony H. Goldstone, Susan Richards, Hillard M. Lazarus, Martin S. Tallman, Georgina Buck, Adele K. Fielding, Alan K. Burnett, Raj Chopra, Peter H. Wiernik, Letizia Foroni, Elisabeth Paietta, Mark R. Litzow, David I. Marks, Jill Durrant, Andrew McMillan, Ian M. Franklin, Selina M. Luger, Niculae Ciobanu, Jacob M. Rowe	537
14	Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia 2004 ·The Lancet ·Adolfo A. Ferrando, Donna Neuberg, Richard K. Dodge, Elisabeth Paietta, Richard A. Larson, Peter H. Wiernik, Jacob M. Rowe, Michael A. Caligiuri, Clara D. Bloomfield, A. Thomas Look	104
15	Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993) 2004 ·Leukemia & lymphoma ·Janice P. Dutcher, Sandra Lee, Robert J. Gallagher, Adel Makary, John Hines, (unknown), John P. Farnen, John M. Bennett, Elisabeth Paietta, Jacob M. Rowe, Olga Goloubeva, Peter H. Wiernik	7
16	Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial. 2003 ·Blood ·Reena Chopra, A H Goldstone, Georgina Buck, S Richards, Ian M. Franklin, H M Lazarus, (unknown), Martin S. Tallman, H. G. Prentice, Jill Durrant, Jacob M. Rowe	1
17	Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): Results from the International ALL trial (MRC UKALL XII/ECOG E2993). 2001 ·Blood ·Jacob M. Rowe, Stephanie Richards, Alan K. Burnett, P H Wiernik, G Harrison, H M Lazarus, I M Franklin, G Prentice, Jill Durrant, Martin S. Tallman, A. H. Goldstone	21
18	Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993). 1999 ·Blood ·A H Goldstone, Stephanie Richards, P H Wiernik, I M Franklin, Alan K. Burnett, H M Lazarus, H. G. Prentice, Donna Neuberg, Martin S. Tallman, G Harrison, Jacob M. Rowe	1
19	The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. 1994 ·PubMed ·Elisabeth Paietta, J. Andersen, Robert E. Gallagher, (unknown), Juan J. Yunis, Peter A. Cassileth, Jacob M. Rowe, Peter H. Wiernik	103
20	Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines 1994 ·Leukemia Research ·Jane L. Liesveld, Peter C. Keng, Jacob M. Rowe, John F. DiPersio, Camille N. Abboud	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact